Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

New indications for Prostaglandin E Synthase inhibitors, verification in human tissue

Reference number
Coordinator Gesynta Pharma AB
Funding from Vinnova SEK 300 000
Project duration December 2017 - December 2018
Status Completed
Venture Innovative Startups

Purpose and goal

The aim of Gesynta´s project was to study the effects of mPGES-1 inhibitors on vascular physiology, specifically with regard to vasodilation in human tissue samples. The mechanism includes a shunting effect to vasodilatory prostacyclin. We could show that mPGES-1 inhibition has a positive effect through its vasodilatory properties and that this is linked to shunting.

Expected effects and result

mPGES-1 inhibitors display a vasodilatory effect that we now verified in two human systems. Both in intermediate arteries from breast tissue and small arteries taken close to fat biopsies. These results open the way for clinical studies of indications where the combination of an anti-inflammatory and vasodilatory effect of mPGES-1 inhibition is potentially beneficial.

Planned approach and implementation

Human tissue (vessels) from biopsies were incubated in organ baths and contractility was measured after addition of physiological stimulators. The Gesynta synthesised mPGES-1 inhibitors were added and effects on the contraction were analyzed. The mechanism for shunting could be verified using prostacyclin receptor antagonists.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 4 December 2018

Reference number 2017-04031

Page statistics